Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies

Doxorubicin cardiotoxicity has led to the development of superior chemotherapeutic agents such as AD 198. However, depletion of healthy neutrophils and thrombocytes from AD 198 therapy must be limited. This can be done by the development of a targeted drug delivery system that delivers AD 198 to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittal, Nivesh K., Mandal, Bivash, Balabathula, Pavan, Setua, Saini, Janagam, Dileep R., Lothstein, Leonard, Thoma, Laura A., Wood, George C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027244/
https://www.ncbi.nlm.nih.gov/pubmed/29662041
http://dx.doi.org/10.3390/pharmaceutics10020050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027244/
https://www.ncbi.nlm.nih.gov/pubmed/29662041
http://dx.doi.org/10.3390/pharmaceutics10020050

Ejemplares similares